Figure 1: Antibody design to improve homogeneity ... Thus, decreasing costs is an important part of drug development. The IgG-based biotherapeutic agents that have been approved in the past ...
Even CMS’s projected cost to Medicare of $550 million for Leqembi ... will be prescribed Leqembi or another monoclonal antibody like it that targets beta amyloid plaque build-up in the brain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback